STING1 and neoplasm: The presence of a human autoimmune phenotype (SAVI) and an ever-expanding number of pre-clinical and clinical studies support the potential for numerous STING agonist compounds in boosting anti-tumor immunity and enhancing the effects of existing immunotherapies.